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Background: Soshiho-tang (SST) is a traditional medicine widely used for the treatment of chronic hepatitis. SST
has been shown to confer a variety of pharmacological activities, including prevention of hepatotoxicity, promotion
of liver regeneration, and modulation of liver fibrosis. In this study, we investigated the antiproliferative activity of
native and fermented (FSST) formulations of SST in vascular smooth muscle cells (VSMCs) and examined the
potential underlying mechanisms driving these effects.
Methods: SST, along with preparations fermented with Lactobacillus plantarum KFRI-144 (S-A144), L. amylophilus
KFRI-161 (S-A161) and L. bulgaricus KFRI-344 (S-A344), were investigated to determine their effects on the proliferation
and viability of VSMCs, along with the signalling pathways underlying these effects.
Results: S-A144 exhibited a strong, dose-dependent inhibition of VSMC proliferation relative to untreated controls, but
the others did not affect. In addition, S-A144 significantly decreased the phosphorylation of Akt and PLCγ1 in a
dose-dependent manner and induced cell cycle arrest at the G0/G1 phase characterised by decreased expression
of CDKs, cyclins and PCNA.
Conclusions: The findings suggest that S-A144 exhibit enhanced inhibition of PDGF-BB-induced VSMC proliferation
comparison to S-AOR through the suppression of cell cycle progression and expression of cell cycle-related proteins,
along with the downregulation of Akt phosphorylation.
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Abnormal proliferation and migration of vascular smooth
muscle cells (VSMCs) are key events in the pathogenesis
of vascular proliferative diseases, such as atherosclerosis
and restenosis [1-3]. Following vascular injury, abnormal
VSMCs transition to a proliferative phenotype charac-
terised by increased expression of cell cycle and prolifera-
tion genes [4]. The cell cycle is a common point of
convergence for the mitogenic signalling cascades, which
consists of four distinct sequential phases (G0/G1, S, G2
and M). Major check points are controlled by multiple
protein kinases, such as cyclin component and a catalytic
cyclin-dependent kinase (CDK) [4,5].* Correspondence: jyma@kiom.re.kr
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reproduction in any medium, provided the orOne of the principal regulators of migration and subse-
quent proliferation in VSMCs is platelet-derived growth
factor (PDGF)-BB, which is secreted by VSMCs and endo-
thelial cells following injury [6-8]. Signalling through the
PDGF receptor is mediated through interactions with
multiple SH2 domains including phospholipase-C
(PLC) γ1, phosphatidylinositol 3-kinase (PI3K) and Ras/
Raf-1 [9]. PDGF-BB activates the extracellular-regulated
kinases (ERK) via Ras/Raf-1, and Akt via PI3K [10,11],
triggering downstream signal transduction and cell cycle
progression [12,13]. As ERK1/2 and Akt are the major sig-
nal transduction proteins involved in the regulation of
proliferation and differentiation [14-16], these pathways
are important for the development of vascular disease by
VSMCs.
Soshiho-tang (SST) is a traditional medicine widely
used for the treatment of chronic hepatitis [17,18]. SST. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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activities, including prevention of hepatotoxicity, promo-
tion of liver regeneration and modulation of liver fibrosis
[19-21]. However, the antiproliferative activity of SST in
VSMCs thus far has not been explored.
Fermentation with pharmaceutical fungal species has
been shown to improve the therapeutic effect of some
herbal medicines [22-24]. Fermentation has been sug-
gested to increase the concentration of bioactive compo-
nents, such as antioxidants, reduce the risk of ethanol-
induced liver toxicity and improve the anti-inflammatory
activity of many compounds [2,23,25]. In this study, we
investigated the antiproliferative activity of SST in VSMCs
in both fermented (FSST) and unfermented forms.
Methods
Materials
Ginseng Radix, Pinellia Tuber, Bupleurum Root, Glycyr-
rhizae Radix et Rhizoma, Scutellaria Root, Zingiberis
Rhizoma Crudus and Zizyphi Fructus were purchased
from Yeongcheon herbal market (Yeongcheon, Korea).
Identification of all plant material was confirmed by
Prof. Ki Hwan Bae of the College of Pharmacy, Chungnam
National University (Daejeon, Korea), and all voucher
specimens were deposited in the herbal bank in Korea
Institute of Oriental Medicine (KIOM, Daejeon, Korea).
Dulbecco’s Modified Eagle Medium (DMEM) was
purchased from Lonza (Wakersville, MD, USA). Fetal
bovine serum (FBS) and phosphate-buffered saline
(PBS) were purchased from Hyclone (Longan, UT,
USA). Penicillin/streptomycin and trypsin/EDTA were
purchased from Gibco (Grand Island, NY, USA). Anti-
phospho-ERK1/2, anti-phospho-Akt, anti-phospho-PLCγ1,
anti-ERK1/2, anti-Akt, anti-PLCγ1, anti-CDK2, anti-CDK4,
anti-cyclin D1, anti-cyclin E1 and anti-β-actin antibodies
were from Cell Signaling Technology Inc. (Beverly, MA).
Anti- phospho-proliferating cell nuclear antigen (PCNA)
was purchased from Abfrontier (Seoul, Korea). PDGF-BB
was obtained from Upstate Biotechnology (Lake Placid, NY,
USA). Cell Counting Kit-8 (CCK-8) was purchased from
Dojindo Molecular Technologies (Rockville, MD, USA).
Other chemicals were of analytical grade.
Preparation of SST extract
SST was prepared according to previously reported method
[19]. Briefly, 1674.5 g medicinal herbal drug, including
Bupleurum Root 600 g, Glycyrrhizae Radix et Rhizoma
100 g, Ginseng Radix 200 g, Pinellia Tuber 200 g, Scutellaria
Root 400 g, Zingiberis Rhizoma Crudus 74.5 g and Zizyphi
Fructus 100 g, was decocted with 16.745 L of boiling water
in stainless oven for 3 h at 115°C using a Gyeongseo
Extractor Cosmos-600 (Incheon, Korea), and then the
decoction was filtered using standard testing sieves
(150 μm; Retsch, Haan, Germany). Then, the filtratewas lyophilized and stored in desiccators at 4°C. For
the fermentation of SST extract, the freeze-dried
extract powder was then dissolved in distilled water,
and kept at 4°C. In addition, for the experiment of
this study, the freeze-dried extract powder was then
dissolved in 50% dimethyl sulfoxide (DMSO, v/v with
phosphate buffered saline) and filtered (pore size, 0.2 μm),
and kept at 4°C (S-OR).
Fermentation of SST extract
In this study, Lactobacillus plantarum KFRI-144 (S-A144),
Lactobacillus amylophilus KFRI-161 (S-A161) and Lacto-
bacillus bulgaricus KFRI-344 (S-A344) used with the fer-
mentation of SST was derived from Korea Food Research
Institute (KFRI, Seongnam-si, Korea). Two successive
transfers of the test organisms in MRS broth (10 g/L pep-
tone, 10 g/L beef extract, 5 g/L yeast extract, 20 g/L glu-
cose, 1 mL/L Tween 80, 2 g/L K2HPO4, 5 g/L sodium
acetate, 2 g/L triammonium citrate, 0.2 g/L MgSO4∙7H2O,
0.2 g/L MnSO4∙4H2O, pH 6.2-6.6) for lactobacilli culture
at 37°C for 24 h, and then the activated cultures were again
inoculated into broth. It was properly diluted to obtain an
initial population of 1–5 × 106 CFU/mL and served as the
inoculum. The viable cell count of strain was determined
in duplicate by using the pour-plate method on MRS agar.
In fermentation process, 5 mL of SST was inoculated with
0.05 mL of the inocula as above, and then this was incu-
bated at 37°C for 48 h. At an interval of 24 h, fermented
SSTs were collected and were analyzed pH. Lactobacillus
plantarum KFRI-144 (S-A144), Lactobacillus amylophilus
KFRI-161 (S-A161) and Lactobacillus bulgaricus KFRI-344
(S-A344) were selected as the high acid-production using
pH analysis and 1st screening test of antiproliferative
activity.
Cell culture
Rat aortic VSMC were purchased from BioBud (Seong-
nam, Korea), which was isolated by enzymatic dispersion
as previously described [26,27]. VSMC was cultured in
DMEM, supplemented with 10% FBS, 100 IU/mL peni-
cillin, 100 μg/mL streptomycin, 8 mM HEPES and
2 mM L-glutamine at 37°C in a humidified atmosphere
of 95% air and 5% CO2 incubator. The purity of VSMC
culture was confirmed by immunocytochemical
localization of α-smooth-muscle actin. The passage
number of VSMC used in this experiment was with 5–7.
Cell proliferation assay
VSMC was measured by both direct counting and non-
radioactive colorimetric WST-1 assay (CCK-8, Takara,
Japan). For direct cell counting, rat aortic smooth
muscle cells were seeded into 12-well culture plates at
4×104 cells/mL, and then cultured in DMEM containing
10% FBS at 37°C for 24 h. After reaching at ~70% of
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medium for 24 h, treated with SST (S-OR) and FSST
formulas (S-AOR, S-A144, S-A161, and S-A344) for an-
other 24 h in newly fresh serum-free medium and stimu-
lated by PDGF-BB (25 ng/mL). After 24 h the cells were
trypsinized by trypsin-EDTA and counted by using
hemocytometer under microscopy. For nonradioactive
colorimetric WST-1 assay, all experimental procedures
were performed as recommended by manufacturer’s in-
structions, and the results were expressed as percentage
of PDGF-BB-stimulated control.
Cell viability assay
VSMC was seeded into 96 well culture plates at 3×104
cells/mL, and then cultured in DMEM containing 10%
FBS at 37°C for 24 h. After reaching at 70% of conflu-
ence, the cells were incubated with serum-free medium
for 24 h. The cells were exposed to 500 μg/mL S-A144
or 50 μM digitonin as a cytotoxic control at various
times. WST-1 reagent was added to the medium, and
the cells were incubated for an additional 2 h. The ab-
sorbance was measured at 450 nm using a
spectrophotometer.
Cell cycle progression analysis
The measurement of cell cycle progression was per-
formed as previously described [26,27]. The assay condi-
tion was the same as described in the section of cell
proliferation assay. After being stimulated by PDGF-BB
(25 ng/mL) for 24 h, cells were trypsinized and centri-
fuged at 1,500 × g for 7 min. The centrifuged pellets
were suspended in 1 mL of 1 × PBS, washed twice, and
fixed with 70% ethanol for 48 h. The fixed cells were
briefly vortexed and centrifuged at 15,000 × g for 5 min.
The ethanol was discarded and the pellets were stained
with 500 μL propidium iodide (PI) solution (50 μg/mL
PI in sample buffer containing 100 μg/mL of RNase A).
Before flow cytometry analysis, each sample was incu-
bated at room temperature for 1 h. The PI-DNA com-
plex in each cell nucleus was measured with
FACScalibur (Becton & Dickinson Co.). The individual
nuclear DNA content was reflected by fluorescence in-
tensity of incorporated PI. The rate of the cell cycle
within G0/G1, S and G2/M phase was determined by
analysis with Modfit LT software.
Immunoblotting assay
Immunoblotting assay was performed as previously de-
scribed [26,27]. Rat aortic smooth muscle cells were
stimulated with PDGF-BB (25 ng/mL) for 5 min for ERK
1/2 and PLCγ1, 15 min for Akt phosphorylation assays.
For the assay of CDK2, CDK4, cyclin D1, cyclin E1 and
PCNA expressions, VSMC were stimulated by PDGF-BB
(25 ng/mL) for 24 h. The detected proteins werenormalized by β-actin or respective total proteins, re-
spectively. The intensities of bands were quantified using
a Scion-Image for Window Program (Scion Corporation,
MA).
Statistical analysis
Data were expressed as means ± S.E.M. Statistical com-
parisons were conducted via one-way analysis of vari-
ance (ANOVA) followed by Dunnett’s test to determine
which groups differed significantly from the control
group. Comparison of the two groups was conducted via
an unpaired Student’s t test (GraphPad, San Diego,
USA). A p value of < 0.05 was considered significant.
Results
Effects of SST and FSST on VSMC proliferation
To compare the antiproliferative effects of SST formulas
on VSMCs, we performed colourimetric WST-1 and
cell counting assays. Among the FSST formulas, SST
fermented with Lactobacillus plantarum KFRI-144
(S-A144) exhibited the strongest inhibition of PDGF-
BB-induced proliferation in VSMCs (Figure 1A). This
effect was stronger than that of S-AOR, a sterilised
formulation of SST.
In cell counting assays, treatment of VSMCs with
25 ng/mL PDGF-BB significantly increased cell prolifera-
tion after 24 h (Figure 1A). Pretreatment of cells with
500 μg/mL S-A144 significantly reduced VSMC prolifer-
ation to 4.0 ± 0.3 × 104 cells/well (Figure 1B). Further
analysis of compound S-A144 alone showed a
concentration-dependent inhibition of VSMC prolifera-
tion (Figure 2A), with cell numbers decreased signifi-
cantly to 8.9 ± 0.5 (100 μg/mL), 6.8 ± 0.4 (300 μg/mL)
and 5.7 ± 0.4 × 104 cells/well (500 μg/mL) compared with
9.4 ± 0.4 × 104 cells/well for PDGF-BB treatment controls
(Figure 2B). These antiproliferative effects were not due
to enhanced cytotoxicity, as even the highest concentra-
tion of S-A144 (500 μg/mL) exhibited no cytotoxicity in
serum-free medium (Figure 2C). In contrast, 50 μg/mL
digitonin as a positive cytotoxic control was cytotoxic
[26,28].
Effects of S-A144 on ERK1/2, Akt and PLCγ1 activation
Our previous study demonstrated that early signal, such
as Akt, ERK1/2 and PLCγ1 phosphorylation, is import-
ant signal transduction in hyper-proliferation of VSMCs
[26,29]. Hence, to investigate the role of early signalling
events in the antiproliferative activity of S-A144, phos-
phorylation of Akt, ERK1/2 and PLCγ1 was measured in
VSMCs following stimulation with PDGF-BB. As shown
Figure 3, S-A144 significantly decreased the phosphoryl-
ation of Akt and PLCγ1 in a concentration-dependent
manner, but ERK1/2 phosphorylation was unaffected.
The inhibitory effect of S-A144 on Akt phosphorylation
Figure 2 Effect of S-A144 on VSMC proliferation and viability. VSMCs cultured in serum-free medium were stimulated with 25 ng/mL
PDGF-BB for 24 h, and the effect of various concentrations of S-A144 (100–500 μg/mL) or S-AOR (500 μg/mL) on cell proliferation and viability
was measured. (A) Cell proliferation was determined using a colourimetric WST-1 assay read at 450 nm (n = 4). (B) Cells were counted using a
haemocytometer (n = 3). (C) VSMCs were treated with 500 ng/mL S-A144 for 24 h; cell viability was determined using a WST-1 assay read at
450 nm (n = 4). Digitonin was used as a positive cytotoxic control. Values are expressed as mean ± S.E.M. Statistically significant differences relative
to PDGF controls (PDGF-stimulated) are indicated by *P < 0.05 and **P < 0.01.
Figure 1 Effects of SST and FSST formulas on VSMC proliferation and viability. VSMCs were seeded into 12-well plates at 4 × 104 cells/mL
and cultured in DMEM containing 10% FBS at 37°C for 24 h. The cells were then incubated in serum-free medium for 24 h, treated with SST
(S-OR) or FSST formulas (S-AOR, S-A144, S-A161 and S-A344) for another 24 h in fresh serum-free medium and stimulated by PDGF-BB
(25 ng/mL). (A) Cell proliferation was determined using a colourimetric WST-1 assay read at 450 nm (n = 4); (B) cells were counted using a
haemocytometer (n = 3). Values are expressed as the mean ± S.E.M. Statistically significant differences relative to PDGF controls (PDGF-stimulated)
are indicated by *P < 0.05 and **P < 0.01.
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Figure 3 Effects of S-A144 on the PDGF-induced activation of ERK1/2, Akt and PLCγ1. Quiescent VSMCs cultured in serum-free medium
were stimulated with 25 ng/mL PDGF-BB, followed by the addition of various concentrations of S-A144 (100–500 μg/mL) or S-AOR (500 μg/mL)
to determine the effect on phosphorylation of ERK1/2, Akt and PLCγ1, as measured by SDS-PAGE and immunoblotting. Total ERK1/2, Akt or β-actin
were used for normalisation. Data are representative of three independent experiments. Values are expressed as the mean ± S.E.M. Statistically
significant differences relative to PDGF controls (PDGF-stimulated) are indicated by **P < 0.01.
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(48.0 ± 4.7% and 100.2 ± 4.2%, respectively). These re-
sults indicate that the antiproliferative action of S-A144
derived by inhibition of Akt and PLCγ1 phosphorylation,
the activity enhancement of S-A144 comparison with S-
AOR was due to the suppression of PI3K-mediated sig-
nalling pathway.
Effect of S-A144 on cell cycle progression
We next examined the effects of PDGF-BB and S-A144
on cell cycle progression. The addition of PDGF-BB to
VSMCs cultured in serum-free media resulted in consid-
erable synchronisation in the G0/G1 phase (74.2 ± 1.8%);
another 17.0 ± 2.0% of the cells were in S phase (Figure 4A).
Following treatment with S-A144, the percentage of
cells in G0/G1 phase increased in a dose dependentmanner, ranging from 83.3 ± 1.9 (100 μg/mL) to 92.9 ±
0.8% (500 μg/mL), respectively. Taken together, these
results show that the antiproliferative effects of S-A144
result in the arrest of cells in G0/G1 phase through the in-
hibition of specific signalling pathways, including Akt and
PLCγ1.
Effect of S-A144 on cell cycle-related protein expression
Cell cycle progression is strictly regulated through the
expression of cell cycle-related proteins, such as CDK2,
CDK4, cyclin D1, cyclin E1 and PCNA [5]. To demon-
strate the mechanism of S-A144-induced the arrest of
cell cycle, we investigated the effect of S-A144 on
CDK2, CDK4, cyclin D1 and cyclin E1 expression. The
result shown in Figure 4B represented that S-A144
inhibited the expression of CDK 2, CDK4 and cyclin
Figure 4 Effects of S-A144 on cell cycle progression and cell cycle-related protein expression in PDGF-BB-stimulated VSMCs. VSMCs
cultured in serum-starved medium were stimulated with 25 ng/mL PDGF-BB, followed by the addition of various concentrations of S-A144
(100–500 μg/mL) or S-AOR (500 μg/mL) to determine the effects on DNA synthesis. (A) Cell cycle progression data are representative of
three independent experiments. (B) CDKs, cyclins and PCNA expression were measured by SDS-PAGE and immunoblotting; total β-actin was
used for normalisation. Immunoblots were analysed by densitometry; values indicate the level of expression relative to controls. Data are
representative of three independent experiments. All values are expressed as the mean ± S.E.M.
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of S-A144 on cyclin E1 expression, S-A144 only inhib-
ited at a concentration of 500 μg/mL, however, S-AOR
at the same concentration did not affect. Moreover, in
other cell cycle-related protein expression, S-A144 was
greater than S-AOR. In addition, expression of PCNA,
synthesised as a phosphorylated retinoblastoma (Rb)
protein-mediated gene product in early G0/G1 and S
phase, was also inhibited by S-A144 (Figure 4B). This
effect was significantly greater for S-A144 than S-AOR,
suggesting that the enhanced antiproliferative effects
of S-A144 compared to S-AOR occur via arrest in
G0/G1 phase through inhibition of cell cycle-related
protein expression.Discussion
This study demonstrated that fermentation of SST en-
hanced the antiproliferative effects of this compound on
VSMCs. This enhanced effect occurred via arrest in the
G0/G1 phase through inhibition of Akt phosphorylation
and cell cycle-related protein expression.
Cardiovascular disease is a complex condition stem-
ming from a variety of physiological processes, including
VSMC proliferation, hypertension and inflammation
[30,31]. Among these causes, VSMC proliferation plays a
central role in the pathogenesis of atherosclerosis and
restenosis after vascular injury, and possibly in the de-
velopment of hypertension [4,32]. For the clinical appli-
cation, research on the VSMC proliferation has been
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opment of bio-stent, the suppression of neointima for-
mation after balloon injury, and the importance of
VSMC proliferation after vascular injury and stenting
[33-35]. Controlling VSMC proliferation may therefore
be important for the treatment of cardiovascular dis-
order and atherosclerosis [26,36].
Fermentation has recently been shown to confer bene-
ficial effects on VSMC proliferation, including inhibition
of proliferation and migration of SMCs by Chungtae-
jeon, a Korean fermented tea, and the vasoprotective ef-
fects mediated by the nonalcoholic constituents of red
wine [37,38]. To identify the mechanism by which fer-
mentation enhanced the antiproliferative activity of SST,
we investigated a variety of SST fermentation formulas
including eight strains of Lactobacillus and two strains
of Bifidobacterium (data not shown) compared with S-AOR,
a sterilised formulation of SST. From these preliminary stud-
ies, we selected three strains of Lactobacillus that exhibited
the strongest effect on SST antiproliferative activity. In
Figure 1, we describe several SST fermentation formu-
las, with S-A144 exhibiting the strongest antiprolifera-
tive effect on VSMCs.
S-A144 significantly inhibited PDGF-BB-induced VSMC
proliferation in a dose-dependent manner (Figure 2).
Moreover, Akt and PLCγ1 phosphorylation were iden-
tified as possible molecular mechanisms by which S-A144
inhibited cell proliferation.
PDGF-mediated cellular proliferation is a highly regu-
lated process involving PLCγ1, PI3K and mitogen acti-
vated protein (MAP) kinase activation [39,40]. PLCγ1
phosphorylation modulates the downstream signal trans-
duction of a variety of growth factors, including PDGF
[9]. S-AOR significantly inhibited PDGF-BB-induced
PLCγ1 phosphorylation, but did not inhibit AKT phos-
phorylation. These data therefore indicate that PLCγ1
may be a target of S-AOR in VSMCs. In contrast, S-A144
showed a greater inhibitory effect on Akt phosphorylation
than S-AOR (Figure 3), indicating that fermentation-
related products were modulating Akt activity.
Akt, a serine/threonine protein kinase, is phosphory-
lated through the PI3K pathway and is important in regu-
lating cell cycle progression [11], which is modulated by
regulatory factors, including cyclin and CDKs, with pRb
considered an important inhibitor of proliferation [5,10].
VSMC proliferation is modulated primarily by regula-
tion of the cell cycle, S-A144 inhibited cell cycle pro-
gression by arresting cells in G0/G1 phase (Figure 4A).
This tightly regulated temporal progression is controlled
by the sequential activation of CDKs and their subunits,
cyclins that phosphorylate the Rb protein. S-A144 also
inhibited the cell cycle-related protein involving CDKs,
cyclins, and PCNA expression (Figure 4B), which is syn-
thesised as a pRb phosphorylation-mediated geneproduct required for the G0/G1 to S phase transition
[41], consistent with the effects seen on cell cycle pro-
gression. These effects were greater for S-A144 than S-
AOR, suggesting that S-A144 may exhibit enhanced in-
hibition of cell cycle progression and expression of cell
cycle-related proteins via the inhibition of Akt
phosphorylation.
Conclusions
This study demonstrates that S-A144, an SST formulation
fermented with L. plantarum, exhibit enhanced inhibition
of PDGF-BB-induced VSMC proliferation comparison to
S-AOR through the induction of cell cycle arrest at the
G0/G1 phase and inhibition of CDKs, cyclins and PCNA
expression. This inhibition may be mediated through a
downregulation of Akt phosphorylation. Together, these
data suggest that S-A144 may be useful in the prevention
of atherosclerosis and restenosis.
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